amoxicillin + furazolidone + esomeprazole

Amoxicillin + furazolidone + esomeprazole is an investigational combination antibiotic and acid-suppression regimen used for the treatment of *Helicobacter pylori* (*H. pylori*) infection, particularly in patients who have failed prior eradication therapy. The regimen combines two antibiotics with distinct mechanisms: amoxicillin, a beta-lactam that inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, and furazolidone, a nitrofuran that induces bacterial DNA damage and oxidative stress. These are paired with esomeprazole, a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase pump. The PPI increases gastric pH, which stabilizes the antibiotics and enhances their antimicrobial efficacy against *H. pylori*. This specific combination is being evaluated in clinical trials, such as those led by Shandong University, often as part of a quadruple therapy (which may also include bismuth) to determine optimal retreatment timing and regimen selection.

Other names

amoxicillin, furazolidone, esomeprazoleamoxicillin + furazolidone + esomeprazole